Home › Compare › JTTRY vs ABBV
JTTRY yields 2.11% · ABBV yields 3.06%● Live data
📍 JTTRY pulled ahead of the other in Year 4
Combined, JTTRY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JTTRY + ABBV for your $10,000?
Japan Airport Terminal Co., Ltd. primarily engages in the management of passenger terminal buildings in Japan. It operates through three segments: Facilities Management, Merchandise Sales, and Food and Beverage. The company constructs, manages, and operates domestic passenger terminal buildings; rents offices, stores, and other facilities to airline companies and airport concessionaires; and operates and manages parking lots. It is also involved in the operation of merchandise stores in domestic and international terminals, including stores in the lobby; and provision of airport passenger, travel insurance agency, and hotel reservation services, as well as rental of halls and conference rooms. In addition, the company engages in the international and domestic travel sales, and ticket sales for transportation and events; and management and operation of Haneda Airport Wharf. Further, it is involved in the wholesale of duty-free goods; operation of commissioned duty-free shops at the Narita International Airport, Kansai International Airport, and Central Japan International Airport; and the product sales at Chengdu Shuangli International Airport. Additionally, the company operates restaurants; and manufactures and sells in-flight meals, box meals, retort food, etc. Japan Airport Terminal Co., Ltd. was incorporated in 1953 and is headquartered in Tokyo, Japan.
Full JTTRY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.